OBJECTIVES The objective is to investigate the interaction of sclero-embolic and contrast agents with the polymerisation of medical grade n-butyl-cyanoacrylates. METHODS An in vitro spectrophotometric absorbance method was developed to detect changes in light transmission to measure n-BCA polymerisation. The initiation and the rate-of-polymerisation of mixtures of n-BCA with sclero-embolic and contrast agents were investigated. RESULTS Initiation of polymerisation: VENABLOCK™ and HISTOACRYL® were the fastest agents to polymerise, while VENASEAL™ was the slowest. Rate of polymerisation: Hypertonic saline inhibited the polymerisation of all n-BCAs, while hypertonic glucose prolonged the polymerisation rate. ETHANOL and detergent sclerosants had no effect. Contrast agents OMNIPAQUE™ and ULTRAVIST® initiated and prolonged the polymerisation of n-BCA, but in contrast, LIPIODOL® failed to initiate the process. CONCLUSIONS The commercially available medical cyanoacrylates differ in their polymerisation rates. These polymerisation rates are further affected when these products are used in conjunction with other compounds, such as sclero-embolic and contrast agents.

中文翻译：

---

氰基丙烯酸酯的聚合：硬化栓塞剂和造影剂的作用。

目的 目的是研究硬化剂和造影剂与医用级氰基丙烯酸正丁酯聚合的相互作用。方法 开发了一种体外分光光度吸光度方法来检测光透射的变化，从而测量 n-BCA 聚合。研究了 n-BCA 与硬化栓塞剂和造影剂的混合物的引发和聚合速率。结果 聚合引发：VENABLOCK™ 和 HISTOACRYL® 是聚合最快的试剂，而 VENASEAL™ 是最慢的。聚合速率：高渗盐水抑制所有n-BCA的聚合，而高渗葡萄糖则延长聚合速率。乙醇和清洁剂硬化剂没有效果。造影剂 OMNIPAQUE™ 和 ULTRAVIST® 引发并延长了 n-BCA 的聚合，但相比之下，LIPIODOL® 未能引发该过程。结论 市售医用氰基丙烯酸酯的聚合速率不同。当这些产品与其他化合物（例如硬化栓塞剂和造影剂）结合使用时，这些聚合速率会受到进一步影响。